Validation/Evaluation of Multimodal Imaging Combining 3D Ultrasound and Stress Myocardial Scintigraphy in the Diagnosis of Coronary Artery Disease

This study has been withdrawn prior to enrollment.
(Impossible to start to the study.)
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nīmes
ClinicalTrials.gov Identifier:
NCT01321970
First received: March 23, 2011
Last updated: August 8, 2014
Last verified: August 2014
  Purpose

Our primary goal is to validate a new diagnostic tool for functional coronary artery stenosis that uses multimodal imaging (combining stress echocardiography and stress scintigraphy) in patients with known coronary chest pain.


Condition Intervention
Coronary Artery Disease
Coronary Disease
Procedure: Stress ultrasound
Procedure: Scintigraphy
Procedure: Coronary angiography

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Validation and Evaluation of Multimodal Imaging Combining Three-dimensional Ultrasound and Stress Myocardial Scintigraphy in the Diagnosis of Coronary Artery Disease

Resource links provided by NLM:


Further study details as provided by Centre Hospitalier Universitaire de Nīmes:

Primary Outcome Measures:
  • The difference between AUCs for multimodal imaging and scintigraphy [ Time Frame: 4 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The difference between AUCs for multimodal imaging and stress ultrasound [ Time Frame: 4 days ] [ Designated as safety issue: No ]

Enrollment: 0
Study Start Date: June 2013
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Severe coronary artery disease
Patients in this group have coronary artery disease with a stenosis of >70%.
Procedure: Stress ultrasound
Qualitative interpretation of the left ventricular wall motion abnormalities is performed in real time in the resting phase and during pharmacological stress. The translation of quantitative data is then performed for each of the 17 segments on a bulls-eye pattern identical to that of scintigraphy.
Procedure: Scintigraphy
Image acquisition is synchronized to the electrocardiogram. The tomographic sections are represented in the 3 directions of space, the analysis is also done on the classical representation in 17 segments. (Typically used in ultrasound perfusion scintigraphy or PET).
Procedure: Coronary angiography

Performed in interventional cardiology setting using a guide introduced through the radial or femoral artery. The injection of iodine allows opacification of coronary arteries and their visualization by fluoroscopy. The qualitative interpretation of the data is translated in terms of percentage of stenosis of the coronary artery. It is thus considered that the stenosis is significant at over 70% obstruction of the lumenal diameter. This interpretation is made ​​for each of the three main coronary arteries and their tributaries:

  • Right coronary (proximal, middle and distal) and collateral (inter ventricular posterior ventricular posterior retro)
  • Inter ventricular anterior (proximal, middle and distal) and its tributaries (diagonal and septal)
  • Circumflex (proximal, middle and distal) and collateral (first and second marginal)
Coronary artery disease
Patients in this group have coronary artery disease with stenosis < 70%.
Procedure: Stress ultrasound
Qualitative interpretation of the left ventricular wall motion abnormalities is performed in real time in the resting phase and during pharmacological stress. The translation of quantitative data is then performed for each of the 17 segments on a bulls-eye pattern identical to that of scintigraphy.
Procedure: Scintigraphy
Image acquisition is synchronized to the electrocardiogram. The tomographic sections are represented in the 3 directions of space, the analysis is also done on the classical representation in 17 segments. (Typically used in ultrasound perfusion scintigraphy or PET).
Procedure: Coronary angiography

Performed in interventional cardiology setting using a guide introduced through the radial or femoral artery. The injection of iodine allows opacification of coronary arteries and their visualization by fluoroscopy. The qualitative interpretation of the data is translated in terms of percentage of stenosis of the coronary artery. It is thus considered that the stenosis is significant at over 70% obstruction of the lumenal diameter. This interpretation is made ​​for each of the three main coronary arteries and their tributaries:

  • Right coronary (proximal, middle and distal) and collateral (inter ventricular posterior ventricular posterior retro)
  • Inter ventricular anterior (proximal, middle and distal) and its tributaries (diagonal and septal)
  • Circumflex (proximal, middle and distal) and collateral (first and second marginal)

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient must have given his/her informed and signed consent
  • The patient must be insured or beneficiary of a health insurance plan
  • The patient has a documented coronaropathy
  • The patient needs a new coronarography following symptoms indicating a change in his/her coronary disease state

Exclusion Criteria:

  • The patient is participating in another study
  • The patient is in an exclusion period determined by a previous study
  • The patient is under judicial protection, under tutorship or curatorship
  • The patient refuses to sign the consent
  • It is impossible to correctly inform the patient
  • The patient is pregnant
  • The patient is breastfeeding
  • Patients with arrhythmias, left bundle branch block on the electrocardiogram which would complicate the interpretation of examinations
  • Unstable, acute coronary syndromes unstable needing emergency coronary angiography
  • Patient with contraindication for conducting a stress test:
  • poorly controlled hypertension
  • pre-existing severe arrhythmia
  • aortic stenosis
  • and obstructive hypertrophic cardiomyopathy
  • Patient has contraindication for atropine
  • History of prostate adenoma
  • Glaucoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01321970

Locations
France
Centre Hospitalier Universitaire de Nîmes
Nîmes Cedex 09, Gard, France, 30029
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nīmes
Investigators
Principal Investigator: Madeleine Rubini, MD Centre Hospitalier Universitaire de Nîmes
  More Information

No publications provided

Responsible Party: Centre Hospitalier Universitaire de Nīmes
ClinicalTrials.gov Identifier: NCT01321970     History of Changes
Other Study ID Numbers: AOI/2009/VB-01
Study First Received: March 23, 2011
Last Updated: August 8, 2014
Health Authority: France: Committee for the Protection of Personnes
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on September 30, 2014